Last reviewed · How we verify
NCT06266572: OASIS
Overcoming Stigma and Improving Outcomes for SUDs Through Education, Engagement, and Empowerment
Phase 1 trial testing Overcoming and Addressing Stigma in Substance Use Disorders (OASIS) in Opioid Use Disorder in 19 participants. Completed in 29 September 2023.
29 September 2023
Quick facts
| Lead sponsor | Center for Social Innovation, Massachusetts |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 19 |
| Start date | 30 September 2021 |
| Primary completion | 29 September 2023 |
| Estimated completion | 29 September 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Overcoming and Addressing Stigma in Substance Use Disorders (OASIS)
Conditions studied
- Opioid Use Disorder — all drugs for Opioid Use Disorder →
Sponsor
Center for Social Innovation, Massachusetts
Who can join
18 and older, any sex, with Opioid Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
C4 Innovations (C4) and partners at Yale University (Yale) and the West Haven VA Medical Center (WHVA) proposed to develop and test OASIS (Overcoming and Addressing Stigma in Substance Use Disorders), a web-based educational platform for primary care clinicians and individuals with Opioid Use Disorder. The major aims of the study were to: 1. Develop a prototype of OASIS for patients with Opioid Use Disorder (OUD) and primary care clinicians; conduct usability testing. 2. Pilot OASIS with a small sample of individuals with untreated OUD and their clinicians to determine feasibility, acceptability, and preliminary product effectiveness for a Phase II effectiveness trial. After development of the prototype, the C4-Yale-WHVA team planned to test OASIS with patients (N = 30) and clinicians (N = 5) using validated measures and qualitative interviews to assess usability, satisfaction, knowledge, empowerment, and stigma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06266572
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid Use Disorder
Currently open trials in the same condition.
- NCT07278518 — Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine · NA · recruiting
- NCT07044466 — Social Functioning in Opioid Use Disorder · NA · recruiting
- NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
- NCT06943859 — Ketamine for Opioid Use Disorder · Phase 2 · recruiting
- NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting
Other Center for Social Innovation, Massachusetts trials
Trials by the same sponsor.
- NCT03390491 — OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis · NA · completed
- NCT03465371 — CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care · NA · completed
- NCT03053557 — Testing a New Device to Advance the Use of Social Skills Training With Mental Health Consumers and Clinicians · NA · completed
- NCT02707367 — Recovery Roadmap Phase II Small Business Innovation Research Grant · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06266572 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Center for Social Innovation, Massachusetts
- Last refreshed: 1 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06266572.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing